Watson Pharmaceuticals has announced a license agreement with GeneraMedix for the exclusive US marketing rights to a generic version of Ferrlecit, a treatment for iron deficiency anaemia.

Ferrlecit (sodium ferric gluconate complex in sucrose injection) is used in the treatment of iron deficiency anaemia in haemodialysis patients receiving supplemental epoetin therapy.

As per the agreement, GeneraMedix will supply the product to Watson, which will market, sell and distribute the product in the US. Terms of the license agreement have not been disclosed.

GeneraMedix currently has an Abbreviated New Drug Application on file with the US Food and Drug Administration (FDA) for a sodium ferric gluconate complex in sucrose product that is packaged in a vial. This application is under expedited review with the FDA.

Watson markets the brand product, Ferrlecit, under a supply and distribution agreement with Sanofi-Aventis. The Ferrlecit product rights will return to Sanofi-Aventis on 31 December 2009.